Catalent, the Somerset-based drug delivery technology company, is investing $10 million to improve capabilities at facilities in Pennsylvania and the U.K., it announced Thursday.
The company said it is making the investment in isolator capabilities at the sites in Malvern and Dartford, respectively, to expand its micronization capabilities for highly potent drug compounds.
“Catalent offers multiple tools and technologies to drug innovators to improve the characteristics and efficacy of new molecules, and micronization is an important engineering step for many materials to help improve the solubility of oral drugs and optimize inhaled therapies,” James Walter, vice president operations, oral and specialty delivery, said in a prepared statement. “This investment allows us to ensure that access to this technology is not limited, as we see the development of highly potent molecules becoming more prevalent in the small molecule (research & development) pipeline against a number of disease targets.”
Work is underway at both facilities, and is expected to be completed by mid-2021, Catalent said.